SCHEMBL24378616

SCHEMBL24378616

Clc1cc(N2CCOCC2)n2cc(Br)cc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 4/20 0.40
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SLC2A1 P11166 1/20 0.36
MEN1 O00255 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 2/20 0.34
GLA P06280 1/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
ALOX5 P09917 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24378615 0.80 CYP1A2 (0.40) CYP1A2CYP2D6MAPTKMT2AKDM4E
SCHEMBL22727799 0.79 POLB (0.43) CYP1A2CYP2D6MAPTKMT2AKDM4E
SCHEMBL23649017 0.77 MAPT (0.44) CYP1A2CYP2D6MAPTKMT2AKDM4E
SCHEMBL27009158 0.72 PIK3CA (0.49) MAPTKMT2AKDM4EALDH1A1SLC2A1
SCHEMBL13263652 0.72 KDM4E (0.56) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL24378575 0.71 KDM4E (0.44) CYP1A2CYP2D6MAPTKMT2AKDM4E
SCHEMBL27009156 0.71 KDM4E (0.56) CYP1A2CYP2D6MAPTKMT2AKDM4E
SCHEMBL27009161 0.71 PDE10A (0.40)
SCHEMBL13263839 0.71 PDE10A (0.54) CYP1A2CYP2D6MAPTKMT2AKDM4E
SCHEMBL13815704 0.70 KMT2A (0.48) CYP1A2CYP2D6MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 CYP1A2 4703/4885CYP2D6 4685/4885MAPT 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.